Q-omics provides the consensus-scored MIR770 profile across patient tissues and cancer cell-line models. MIR770 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, MIR770 is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, MIR770 RNA expression shows 15,593 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BLCA, and THYM as cancer lineages where MIR770 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR770 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR770 survival associations across molecular data types. MIR770 RNA expression shows survival associations in the most cancer types (16), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR770 RNA expression–survival associations across cancer types. High MIR770 expression shows unfavorable associations in BLCA, THCA, COAD, READ and UCEC, but favorable associations in UCS. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for MIR770 RNA expression.
This table summarizes MIR770 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR770. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR770 shows lower tumor expression in BLCA, COAD, BRCA, STAD, LUSC and KICH. The BLCA box plot shows higher MIR770 RNA expression in normal versus tumor tissue (log2 FC = −1.274, t-test p < 0.001).
This table shows molecular features associated with MIR770 in patient tissues and cancer cell lines. In patient samples, MIR770 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
